Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rohit & Rahul Gosain are joined by Dr. Joshua Sabari from the NYU Langone Cancer Center to discuss the exciting recent approval of Zongertinib, the first oral TKI for HER2-positive lung cancer.

We dived deep into the prevalence of HER2 mutations in non-small cell lung cancer, the study design and findings from the Beamion LUNG-1 trial, and the implications of this new therapy in clinical practice. Dr. Sabari shared insights on the efficacy of Zongertinib, including impressive response rates and progression-free survival data, as well as its side effect profile compared to other treatments like trastuzumab deruxtecan (T-DXd).

Key topics covered in this episode:
•⁠ ⁠Overview of HER2 mutations in lung cancer
•⁠ ⁠Study design and results of the Beamion LUNG-1
•⁠ ⁠Comparison of Zongertinib and T-DXd in treatment settings
•⁠ ⁠Management of common side effects associated with Zongertinib
•⁠ ⁠Future directions for HER2-targeted therapies

Join us for this informative discussion as we explore the latest advancements in lung cancer treatment and what they mean for patients and clinicians alike. Don't forget to subscribe for more episodes on new approvals, side effect management, and practice-changing data in oncology!

Follow us on social media:
•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠ Website: https://oncbrothers.com/

Prof. Reinhilde Veugelers of KU Leuven in Belgium on risk aversion in R&D funding